HER2 protein overexpression

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody 1 substance
Unknown / small molecule 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase II: 1 Phase I/II: 1 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2024-516551-41-00 1 country 2026 n=125
    Recruiting

Phase I/II

1 trial
  • Bolt Biotherapeutics Inc. Commercial
    BDC-1001; NIVOLUMAB
    2024-518411-19-00 1 country 2023 n=15
    Ended

Phase I

1 trial
  • Rigshospitalet Academic
    IMP not specified
    2024-516786-37-00 1 country 2025 n=140
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Jazz Pharmaceuticals Ireland Limited Commercial 1 Phase II 1
Bolt Biotherapeutics Inc. Commercial 1 Phase I/II 0
Rigshospitalet Academic 1 Phase I 1
New trials by year
2023
1
2025
1
2026
1
← All indication landscapes